Overview Add Glucokinase Activator to Target A1c Status: Completed Trial end date: 2016-09-01 Target enrollment: Participant gender: Summary This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months. Phase: Phase 2 Details Lead Sponsor: vTv TherapeuticsTreatments: Sitagliptin Phosphate